I think, there is not a big chance that a Technical Board of appeal can challenge this (I am not sure if they could even raise a question to an answer that was already provided by the Enlarged Board).
There is no support from any member state or reliable expert to challenge this.
We asked our lawyers, there is no entry point they could identify.
But if you provide us with better arguments (not only relying on Kock), we can have a look onto it.
If I overlooked some interesting arguments, please let me know.
My understanding of decision is that the EOB had to make a deal: They have to explain why they changed their mind. Therefore, they introduce a new consideration: The understanding of the law has changed (due to our activities ...). If there is change in the interpretation of law, they have to say when the change became manifest.
Thus, if you try to challenge the deadline, you put in question the whole decision G3/19 8and rule 28(2).
I guess, you would need the AC to challenge this. This would mean spending our energy in a revision of G3/19 instead of closing the gaps around 28 (2)...
Am 17.11.20 um 14:47 schrieb francois.meienberg@prospecierara.ch:
I think it would be interesting to challenge the decision not to apply the rule to applications prior to July 2017.
And this could best be done with a case we are involved in.
Maybe the arguments of Kock could be a starting point which have to be further developed.
(Although we all know how long it takes to change decisions taken by the EBA …)
Best
François
*Von:*Npos_2018 npos_2018-bounces@testbiotech.de *Im Auftrag von *Christoph Then *Gesendet:* Dienstag, 17. November 2020 14:39 *An:* npos_2018@testbiotech.de *Betreff:* Re: [Npos_2018] Article Bioscience Law Reveiw
I would not buy these arguments it, although some aspects are interesting. I also would not refer to it, it might confuse the discussion.
Maybe I am wrong, but I guess Kock not seen as a winner in this debate around G3/19 and he tries to encourage his clients.
Am 17.11.20 um 14:01 schrieb ARCHE NOAH Katherine Dolan:
Dear all, François – Thank you for sending around this article, which I now finally got around to reading. It is particularly interesting to read his views on the EBA’s decision not to apply Rule 28(2) to applications prior to July 2017, reinforcing that the decision is not legally watertight. The ship may now have sailed on this point, as the national governments appear to have accepted it. But it raises the question for me if we should be raising this issue in our communications on existing patent cases, e.g. the melon patent? Best Katherine *Von:*Npos_2018 [mailto:npos_2018-bounces@testbiotech.de] *Im Auftrag von *francois.meienberg@prospecierara.ch <mailto:francois.meienberg@prospecierara.ch> *Gesendet:* Samstag, 24. Oktober 2020 12:30 *An:* 'Christoph Then' <christoph.then@testbiotech.org> <mailto:christoph.then@testbiotech.org>; npos_2018@testbiotech.de <mailto:npos_2018@testbiotech.de> *Betreff:* [Npos_2018] Article Bioscience Law Reveiw Dear All Attached a new article by Michael Kock which may be of interest. (not for publication as it is an article of a journal where access is on payment …) Best François *PS*: Etappensieg! Nach über 10 Jahren Kampf zusammen mit der Koalition «No Patents on Seeds» hat das Europäische Patentamt *Patente auf konventionell gezüchtete Pflanzen verboten*. Mehr <https://www.prospecierara.ch/de/erleben/news/news-detail/news/patente-auf-konventionell-gezuechtete-pflanzen-verboten.html> ------------------------------------------------------------------------ *ProSpecieRara* Schweizerische Stiftung für die kulturhistorische und genetische Vielfalt von Pflanzen und Tieren François Meienberg - Projektleiter Saatgutpolitik Tel. direkt +41 (0)61 545 99 19 Sekretariat +41 (0)61 545 99 11 (vormittags) ProSpecieRara, Unter Brüglingen 6, 4052 Basel Spendenkonto CH29 0900 0000 9000 1480 3 www.prospecierara.ch <http://www.prospecierara.ch/> auf Facebook <https://www.facebook.com/ProSpecieRara> auf Instagram <https://www.instagram.com/prospecierara/> _______________________________________________ Npos_2018 mailing list Npos_2018@testbiotech.de <mailto:Npos_2018@testbiotech.de> https://lists.testbiotech.de/cgi-bin/mailman/listinfo/npos_2018
Npos_2018 mailing list Npos_2018@testbiotech.de https://lists.testbiotech.de/cgi-bin/mailman/listinfo/npos_2018